Patient’s profile who takes three drugs and it is worth to alter the scheme of treatment to one three-component pill Review article
Article Sidebar
Main Article Content
Abstract
The main goal of antihypertensive treatment is to reduce blood pressure to target values and if it is impossible to values which are near target values. Lowering high blood pressure is connected with reduction of mortality and global risk of cardiovascular and kidney complications. Choosing appropriate antihypertensive therapy is a very complicated decision which should be individualized. As practice shows monotherapy is usually ineffective. When we have to decide which combined drug we should use we need to apply a drug under the same rules as monotherapy, taking under consideration coexistent diseases, cardiovascular complications and a lot of different aspects. According to the latest recommendations of Polish Hypertension Society in non-complicated hypertension patients basic three-component therapy includes ACE-I, calcium antagonists, thiazide diuretics/thiazide-like diuretics. Unfortunately, even if we apply optimized treatment we cannot meet the therapeutic aim. It is usually connected with not keeping medical recommendation and is a consequence of bad doctor-patient relation. Inappropriate cooperation in hypertensive therapy regards mainly to incorrect scheme taking drugs, as well as changing lifestyle. Good solution to improve compliance and persistence of patients is simplifying therapy taking one three-component pill.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśn. Tętn. Prakt. 2015; 1: 1-70.
3. Claxton A.J., Cramer J., Pierce C. et al.: A systemic review of the associations between dose regimens and medication compliance. Clin. Ther. 2001; 23: 1296-1310.
4. Waeber B., Burnier M., Brunner H.R.: Compliance with antihypertensive therapy. Clin. Exp. Hypertens. 1999; 21: 973-985.
5. Gupta A.K., Arshad S., Poulter N.R.: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407.
6. Dahlöf B., Sever P.S., Poulter N.R. et al.; ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendro umethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
7. Patel A., MacMahon S., Chalmers J., Neal B. et al.; ADVANCE Collaborative Group: Efects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
8. Beckett N.S., Peters R., Fletcher A.E. et al.: HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358: 1887-1898.
9. Bakris G.L., Sera dis P.A., Weir M.R. et al.; ACCOMPLISH Trial Investigators: Renal outcomes with different fixed-dose combination therapies in patients with Hypertension, at high risk for cardiovascular events (ACCOMPLISH): a prespecied secondary analysis of randomised controlled trial. Lancet 2010; 375: 1173-1181.
10. Weber M.A., Julius S., Kjeldsen S.E. et al.: Blood pressure dependent and independent efects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051.
11. Staessen J.A., Thijisq L., Fagard R. et al.; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens. 2004; 22: 847-857.
12. Pepine C.J., Handberg E.M., Cooper-DeHo R.M. et al.; INVEST Investigators: A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. e International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
13. Arima H., Chalmers J., Woodward M et al.: Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J. Hypertens. 2006; 24: 1201-1208.
14. Cooper C.J., Murphy T.P., Cutlip D.E. et al.: Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. CORAL Trial. N. Engl. J. Med. 2014; 370: 13-22.
15. Gorczyca-Michta I., Wożakowska-Kapłon B.: Kiedy i dlaczego w terapii hipotensyjnej wybieram połączenie trójlekowe – perindopril/indapamid/amlodipina? Folia Cardiologica 2016; 11(1): 47-56.